Outgoing Senator Orrin Hatch, R-Utah, is urging fellow Republicans to oppose President Donald Trump’s International Pricing Index; after 12 patients became seriously ill from stem cell injections, the FDA issued a warning to the company that made the product and sent a letter to 20 clinics warning them that stem cell products should be regulated by the agency; Cigna has finalized its $54 billion purchase of Express Scripts.
Outgoing Senator Orrin Hatch, R-Utah, is urging fellow Republicans to oppose President Donald Trump’s International Pricing Index, which would allow Medicare to pay the price other countries pay for certain drugs. According to The Hill, Hatch believes the proposal would curb innovation and deprive patients of future treatment breakthroughs. Hatch also criticized the Center for Medicare and Medicaid Innovation, which he believes has too much power to make changes to Medicare.
After 12 patients became seriously ill from stem cell injections, the FDA issued a warning to the company that made the product and sent a letter to 20 clinics warning them that stem cell products should be regulated by the agency. In the letter, the FDA encouraged the clinics to speak with regulators before 2020, when enforcement of stem cell products will tighten, reported The New York Times. These clinics are located all across the country and offer unapproved stem cell treatments to treat a variety of diseases without proof that they are effective or safe. The 12 hospitalized patients received injections to treat painful conditions like arthritis or injuries, and they all contracted infections in their bloodstreams or joints.
Cigna has finalized its $54 billion purchase of Express Scripts, which creates one of the biggest pharmacy benefits and insurance plans in the United States. According to Reuters, the deal puts Cigna in direct competition with Aetna, which purchased CVS Health, and UnitedHealth Group, which purchased Optum. The Department of Justice cleared the deal on September 17.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT
April 22nd 2024A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen